Reimbursement Coding for Amniotic Membrane Allografts: 2026 Update

Amniotic membrane allografts remain an important advanced wound care option for chronic lower-extremity wounds that have not progressed with standard care. For wound centers, the clinical decision DFU treatment guidelines is only one part of appropriate use. The 2026 reimbursement environment also requires disciplined product coding, application coding, wound measurement, medical-necessity documentation, and payer-specific policy review.

Stay current on broader regulatory shifts FDA compliance overview with our FDA compliance 2026 overview. CMS made material payment changes for skin substitute products effective January 1, 2026. At the same time, CMS announced on December 24, 2025 that the final multi-MAC local coverage determinations for skin substitute grafts in diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), which had been scheduled for January 1, 2026, were withdrawn. The practical result is that coverage analysis still depends heavily on the patient, wound, payer, MAC jurisdiction, and documentation, while Medicare payment methodology has changed nationally.

Clinical Evidence Behind Amniotic Allograft Use

Reimbursement policies increasingly look for evidence-informed selection rather than routine use. Published randomized trials and systematic reviews support amniotic membrane products as adjuncts to standard wound care in selected chronic wounds, especially DFUs and VLUs. In a 2020 systematic review and meta-analysis of seven randomized controlled trials involving 465 participants, human amniotic membrane plus standard care improved complete DFU healing compared with standard care alone at 6 and 12 weeks, with shorter time to closure and no significant increase in adverse events.

Earlier prospective randomized DFU work by Zelen and colleagues found improved healing outcomes with amniotic membrane wound grafts compared with standard care. Subsequent studies explored application frequency, suggesting that weekly application can accelerate time to healing in appropriate patients, although clinical protocols must still be individualized based on wound response, wound bed quality, exudate, infection status, and payer limits.

For VLUs, randomized evidence supports amniotic membrane allografts as an adjunct to multilayer compression in selected nonhealing ulcers. Serena and colleagues reported multicenter randomized data evaluating dehydrated human amnion/chorion membrane plus compression compared with compression alone, and follow-up analyses linked early area reduction with later healing. These studies are not product-identical to every commercially available allograft, but they form part of the broader evidence base that payers and clinicians use when evaluating placental-derived wound biologics.

2026 Medicare Payment and Coding Update

CMS finalized a major shift in how skin substitute products are paid under Medicare. For non-facility physician office use, CMS finalized payment for skin substitutes as incident-to supplies when used as part of a covered application procedure under the Physician Fee Schedule. For hospital outpatient departments, CMS finalized unpackaging skin substitute products from the application services and assigning products to APCs based on regulatory category: PMA products, 510(k) products, and 361 HCT/P products. CMS stated that for 2026 it would use a single payment rate for the categories, with future differentiation possible.

The application codes remain central. CPT codes 15271-15278 describe skin substitute application by anatomic region and wound surface area. In general, trunk, arm, and leg applications use one family of codes, while face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and digits use another. The first-code and add-on-code logic depends on total treated wound surface area. Coding teams should verify the 2026 CPT manual language and payer edits rather than relying on templates built for prior years.

Product coding is reported separately with the applicable HCPCS Level II code when payable under the setting and payer policy. CMS established Q4250 for AmnioAMP-MP, per square centimeter, effective October 1, 2020. For Rampart products or any configuration not clearly mapped in the current HCPCS file, teams should verify the current code assignment, descriptor, payer policy, and manufacturer reimbursement guidance before claim submission. Avoid assuming that one placental product's HCPCS code applies to another product or form factor.

Clinical Protocol Documentation

Strong documentation starts before the first graft. For DFUs, record ulcer duration, diabetes control factors, neuropathy status, offloading plan, vascular assessment, infection evaluation, debridement, depth, tissue type, drainage, undermining, exposed structures, and serial measurements. For VLUs, document compression use, edema control, venous history, arterial sufficiency when relevant, and failure to progress despite appropriate conservative therapy.

At the application visit, the note should include pre-debridement and post-debridement measurements when performed, wound surface area calculation, product size opened, product area applied, any discarded amount if required by payer policy, fixation method, secondary dressing, offloading or compression instructions, and planned reassessment. Photographs are useful when permitted by clinic policy and HIPAA-compliant storage. Wound center coordinators should ensure the clinical note, charge ticket, inventory log, and product lot record tell the same story.

Comparison: CPT, HCPCS, ICD-10-CM, and Modifiers

The most common coding failures occur when teams treat product and procedure coding as interchangeable. CPT application codes report the clinician's work of applying a skin substitute to a defined wound area and body site. HCPCS product codes identify the biologic material and units. ICD-10-CM codes justify the diagnosis and ulcer characteristics. Modifiers, when applicable, explain laterality, repeat services, distinct procedural services, or payer-required facts; they do not repair a medically unsupported record.

Key Takeaways for 2026

• CMS changed payment methodology for skin substitutes in 2026, but coverage still requires patient-specific medical necessity and payer-specific policy review.
• The withdrawn 2026 multi-MAC LCDs did not eliminate the need for careful documentation; they increased the importance of checking current MAC and payer guidance.
• Use CPT 15271-15278 based on anatomic site and total treated wound surface area, and pair the procedure code with the correct product HCPCS code when separately reportable.
• AmnioAMP-MP is identified by HCPCS Q4250; verify current HCPCS assignment for Rampart products and any product configuration before billing.
• Claims are strongest when conservative care failure, wound-bed preparation, product sizing, application details, and follow-up response are documented consistently.

References